Oncology Trials of Antibody Drug Conjugates: Evaluating ILD Toxicity

Antibody Drug Conjugates (ADCs) are one of the fastest-growing classes of cancer drugs in clinical development and have the potential to change the management of cancer patients. Unfortunately, ADCs have been associated with the risk of pulmonary abnormalities, the most concerning of which is drug-induced Interstitial Lung Disease (ILD).

As a result, in clinical trials investigating ADCs for the treatment of cancers, regulatory agencies around the world are asking trial sponsors to monitor for ILD toxicity. Research has shown that early detection, diagnosis, and management can prevent the worsening of ILD in these patients since in many cases the complications are reversible.

This webinar will review the implications of ILD toxicity monitoring in ADC trials. Dr. Sood will present best practices for using HRCT for the detection and characterization of ILD and how, when integrated with clinical and laboratory tests, it provides a consistent and standardized way to adjudicate ILD cases and meet regulators’ expectations.

United States
May 14, 2024


Rohit Sood image

Rohit Sood

Vice President, Scientific & Medical Services

Rohit Sood MD., PhD. is the Vice President of Scientific and Medical Services at Calyx. In his present role as the Emerging Therapeutics Lead, which covers Cardio-Thoracic, CNS, GI, Rare diseases and Advanced Technologies, Dr. Sood has contributed as a consultant/scientific lead on sponsored 160+ imaging clinical trials spanning the entire spectrum, from early to late phase, across multiple therapeutic areas. He was responsible for supporting 20+ drug approval clinical studies that involved imaging as a key trial endpoint. Over the past decade, he has been instrumental in developing partnerships with academic and non-academic labs to leverage Machine and Deep Learning methodologies for application in pharmaceutical drug studies that involve imaging based endpoints. More specifically, using ML/DL methods to analyze images and develop quantitative biomarkers for use as endpoints in clinical trials. The usefulness of some of these biomarkers was evaluated in clinical trials and results were published in peer reviewed scientific journals.

Stay Updated

Never miss a beat. Sign up to receive emails covering industry news and useful content to help you advance clinical development.

  • This field is for validation purposes and should be left unchanged.